• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Genmab A/S - American Depositary Shares (NQ:GMAB)

    29.18 -0.82 (-2.75%)
    Streaming Delayed Price Updated: 12:23 PM EST, Feb 18, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,921,745
    Open 29.25
    Bid (Size) 29.17 (200)
    Ask (Size) 29.18 (300)
    Prev. Close 30.00
    Today's Range 28.84 - 29.52
    52wk Range 17.23 - 35.43
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Genmab A/S (NASDAQ:GMAB): A GARP Case Study in Affordable Biotech Growth ↗
    Via Chartmill
    GENMAB A/S (NASDAQ:GMAB) Stands Out as a Peter Lynch-Style GARP Investment ↗
    Via Chartmill

    Performance

    YTD
    -8.3%
    -8.3%
    1 Month
    -6.9%
    -6.9%
    3 Month
    -3.8%
    -3.8%
    6 Month
    +22.5%
    +22.5%
    1 Year
    +34.0%
    +34.0%

    More News

    Read More
    GENMAB A/S -SP ADR (NASDAQ:GMAB) Combines Strong Growth with Bullish Technical Formation ↗
    Via Chartmill
    GENMAB A/S (NASDAQ:GMAB) Presents a Compelling Blend of Strong Fundamentals and Bullish Technicals ↗
    Via Chartmill
    News headline image
    My Top 4 Stocks to Buy in Early 2026 ↗
    Via The Motley Fool
    Topics Artificial Intelligence Economy
    News headline image
    Genmab Reports Mixed Results From Late-Stage Trial Of Lymphoma Drug ↗
    Via Stocktwits
    GENMAB A/S -SP ADR (NASDAQ:GMAB) Passes Peter Lynch's GARP Investment Screen ↗
    Via Chartmill
    News headline image
    Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    From Genmab A/S
    Via Business Wire
    News headline image
    Why Are Investors Paying Attention To Genmab Stock? ↗
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
    From Genmab A/S
    Via Business Wire
    News headline image
    Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech ↗
    Via Stocktwits
    Topics Supply Chain
    News headline image
    Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
    Via MarketMinute
    Topics ETFs Intellectual Property
    News headline image
    Genmab Portfolio Prioritization Update
    From Genmab A/S
    Via Business Wire
    News headline image
    Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
    From Genmab A/S
    Via Business Wire
    News headline image
    Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
    From Genmab A/S
    Via Business Wire
    News headline image
    Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
    From Genmab A/S
    Via Business Wire
    News headline image
    Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
    From Genmab A/S
    Via Business Wire
    News headline image
    Genmab (GMAB) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer ↗
    Via Benzinga
    News headline image
    Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
    From Genmab A/S
    Via Business Wire
    News headline image
    Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? ↗
    Via Investor's Business Daily
    News headline image
    Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday ↗
    Via Benzinga
    News headline image
    Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
    From Genmab A/S
    Via Business Wire
    News headline image
    Why Is Genmab Stock Trading Lower On Monday? ↗
    Via Benzinga
    News headline image
    Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Genmab A/S - American Depositary Shares publicly traded?
    Yes, Genmab A/S - American Depositary Shares is publicly traded.
    What exchange does Genmab A/S - American Depositary Shares trade on?
    Genmab A/S - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Genmab A/S - American Depositary Shares?
    The ticker symbol for Genmab A/S - American Depositary Shares is GMAB on the Nasdaq Stock Market
    What is the current price of Genmab A/S - American Depositary Shares?
    The current price of Genmab A/S - American Depositary Shares is 29.18
    When was Genmab A/S - American Depositary Shares last traded?
    The last trade of Genmab A/S - American Depositary Shares was at 02/18/26 12:23 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.